Author:
Sharma Homa Nath,Catrett Jonathan,Nwokeocha Ogechi Destiny,Boersma Melissa,Miller Michael E.,Napier Audrey,Robertson Boakai K.,Abugri Daniel A.
Abstract
AbstractToxoplasma gondii (T. gondii) infection continues to rise globally in humans and animals with high socioeconomic and public health challenges. Current medications used against T. gondii infection are limited in efficacy, safety, and affordability. This research was conducted to assess the higher fungi extract effect on T. gondii tachyzoites growth in vitro and possibly decipher its mechanism of action. Furthermore, we evaluated the extract's effect on human foreskin fibroblast viability. The methanol extracts of Turkey tail (TT) mushroom was tested against T. gondii tachyzoites growth using an RH-RFP type I strain that expresses red fluorescent protein throughout culture in a dose-dependent manner using a fluorescent plate reader. Similarly, we tested the effect of the extract on host cell viability. We observed that TT extract inhibited tachyzoites growth with a 50% minimum inhibitory concentration (IC50s), IC50 = 5.98 ± 1.22 µg/mL, and 50% cytotoxic concentration (CC50s), CC50 ≥ 100 µg/mL. It was discovered that TT extract induced strong mitochondria superoxide and reactive oxygen species production and disrupted mitochondria membrane potential in T. gondii tachyzoites. Additionally, scanning electron microscopy depicted that TT extract and pyrimethamine (PY) caused a morphological deformation of tachyzoites in vitro. In conclusion, TT methanol extract made up of phytosterols, bioactive sphingolipids, peptides, phenolic acids, and lactones could be a promising source of new compounds for the future development of anti-Toxoplasma gondii drugs. Extracts were non-cytotoxic, even at higher concentrations.
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Dubey, J. P., Murata, F. H. A., Cerqueira-Cézar, C. K., Kwok, O. C. H. & Villena, I. Congenital toxoplasmosis in humans: An update of the worldwide rate of congenital infections. Parasitology 148, 1716 (2021).
2. Pappas, G., Roussos, N. & Falagas, M. E. Toxoplasmosis snapshots: Global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int. J. Parasitol. 39, 1385–1394 (2009).
3. Flegr, J., Prandota, J., Sovičková, M. & Israili, Z. H. Toxoplasmosis–a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS ONE 9, e90203 (2014).
4. CDC. Parasites-toxoplasmosis (toxoplasma infection): Epidemiology and risk. Retrieved from CDC: Centers for Disease Control Prevention: https://www.cdc.gov/parasites/toxoplasmosis/epi.html. Accessed 01 May 2023 (2023).
5. Montazeri, M. et al. The global serological prevalence of Toxoplasma gondii in felids during the last five decades (1967–2017): A systematic review and meta-analysis. Parasites Vectors 13, 1–10 (2020).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献